1. Alemtuzumab-based therapy for Secondary Malignant Histiocytosis arising from Pre-B-ALL. (2018) Authors: Abid, Muhammad Bilal; Wadhera, Karan; Bird, Jenny M.; Pawade, Joya; Marks, David I. Journal: Leukemia research reports Issue: Volume 9(2018) Page Start: 5 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial. (6th February 2019) Authors: Cook, Gordon; Royle, Kara‐Louise; O'Connor, Sheila; Cairns, David A.; Ashcroft, A. John; Williams, Cathy D.; Hockaday, Anna; Cavenagh, Jamie D.; Snowden, John A.; Ademokun, Debo; Tholouli, Eleni; Andrews, Vivienne E.; Jenner, Matthew; Parrish, Christopher; Yong, Kwee; Cavet, Jim; Hunter, Hannah; ... Journal: British journal of haematology Issue: Volume 185:Number 3(2019) Page Start: 450 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗